PulseMedica, founded in 2018 and headquartered in Edmonton, AB, Canada, is a pioneering player in the ophthalmic treatment landscape. The company is laser-focused on revolutionizing vitreoretinal treatments, guided by its slogan: "Laser Focused on Disrupting Vitreo Retinal Treatments."
PulseMedica has developed a proprietary real-time 3D imaging and laser targeting system designed for precise retinal surgery. Their cutting-edge, next-generation ultrafast femtosecond laser targets retinal diseases like age-related macular degeneration (AMD) and glaucoma, which currently lack definitive cures.
In their latest funding round, PulseMedica secured a substantial $12.00M Seed Round investment on 29 May 2024. This round drew attention from a range of distinguished investors, including Saltagen Ventures, Wisdom LLP, Accelerate Fund, and University of Alberta, underscoring strong confidence in PulseMedica's vision and technological potential.